Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 22 | GlobeNewswire (Europe) | BOSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
Mo | Oppenheimer assigns outperform rating to Praxis Precision Medicines stock | 1 | Investing.com | ||
07.05. | Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside | 1 | Benzinga.com | ||
PRAXIS PRECISION MEDICINES Aktie jetzt für 0€ handeln | |||||
02.05. | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 137 | GlobeNewswire (Europe) | BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
02.05. | Praxis Precision Medicines GAAP EPS of -$3.29 | 1 | Seeking Alpha | ||
02.05. | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
02.05. | Praxis Precision Medicines, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
02.05. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results | 171 | GlobeNewswire (Europe) | On track for six major study readouts across four programs over the next 12 months Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025:... ► Artikel lesen | |
08.04. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies | 1 | GlobeNewswire (USA) | ||
08.04. | Deep Dive Into Praxis Precision Medicine Stock: Analyst Perspectives (8 Ratings) | 1 | Benzinga.com | ||
03.04. | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 225 | GlobeNewswire (Europe) | BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
24.03. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Present on Late-Stage Programs across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting | 2 | GlobeNewswire (USA) | ||
04.03. | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 263 | GlobeNewswire (Europe) | BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
03.03. | Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate | 1 | Benzinga.com | ||
03.03. | Assessing Praxis Precision Medicine: Insights From 5 Financial Analysts | 3 | Benzinga.com | ||
28.02. | Praxis Precision Medicines Plunges 39% After Study Termination Recommendation | 5 | RTTNews | ||
28.02. | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Update on Essential3 and Corporate Update | 345 | GlobeNewswire (Europe) | BOSTON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
28.02. | Praxis Precision Medicines, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
28.02. | Praxis Precision Medicines, Inc. - 10-K, Annual Report | - | SEC Filings | ||
28.02. | Praxis Precision Medicines, Inc. - 8-K, Current Report | - | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,006 | +0,17 % | DAX nach Feiertag wieder bei 24.000 - Douglas, Evotec, Fresenius, Merck, Renk und SAP im Check | An Christi Himmelfahrt hat es am deutschen Aktienmarkt bei dünnen Umsätzen etwas an Boden verloren. Die Verluste macht der DAX aber am letzten Handelstag im Mai schon wieder gut, wobei die Zollpolitik... ► Artikel lesen | |
QIAGEN | 40,130 | -0,37 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
MODERNA | 23,450 | -0,42 % | Kurs von Moderna steigt etwas (24,09 €) | Im US-amerikanischen Wertpapierhandel liegt das Wertpapier von Moderna gegenwärtig im Plus. Die Aktie notiert aktuell bei 24,09 Euro. Die Aktie von Moderna verzeichnet zur Stunde ein Kursplus von 4... ► Artikel lesen | |
AMGEN | 254,85 | +1,51 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
NOVAVAX | 6,275 | +2,50 % | Schock-News für Novavax Anleger vor dem Wochenende: So müssen Sie heute noch auf diese Sondermeldung reagieren! | ||
BIOGEN | 116,05 | +1,80 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
ILLUMINA | 73,13 | +1,67 % | Does Illumina (ILMN) Have Good Long-Term Growth Prospects? | ||
CRISPR THERAPEUTICS | 35,800 | +5,92 % | AKTIONÄR-Depotwert CRISPR Therapeutics: Cathie Wood kauft erneut | Die Aktie des Gen-Schere-Spezialisten CRISPR Therapeutics kommt seit Monaten nicht von der Stelle. Das aktuelle Niveau hat nun aber Cathie Wood zum Kauf genutzt. Die für Donnerstag veröffentlichten... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,930 | +4,32 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
OCUGEN | 0,917 | +9,98 % | Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 7,078 | +7,02 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
COSCIENS BIOPHARMA | 3,240 | -0,61 % | COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders | Reconstituted Board to Revitalize COSCIENS TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) today announced that it has entered into a resolution agreement... ► Artikel lesen | |
EDITAS MEDICINE | 1,660 | +5,77 % | Editas Medicine ändert Aktienplan und erhöht genehmigte Aktien | ||
BIOCRYST PHARMACEUTICALS | 9,610 | +0,15 % | BioCryst Pharmaceuticals, Inc.: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 36,740 | +7,21 % | FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector | WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT), Wednesday announced that the FDA has designated its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 for limb-girdle... ► Artikel lesen |